Thursday 16 October, 2025
Introduction: For certain old, widely used therapies, a plethora of non-compartmental analyses and population pharmacokinetic (popPK) studies are available in…
Read morePoster: Drug/Disease Modelling - Oncology
Modeling tumor growth inhibition in Glioblastoma spheroids after exposure to RC-106, a novel sigma receptors modulator
Thursday 16 October, 2025
Introduction: Glioblastoma (GBM) is an aggressive brain tumor for which there is no effective cure [1,2]. Therefore, there is an…
Read moreTo quantify the association between tumor dynamics and overall survival across cancers: a Bayesian meta-analysis
Thursday 16 October, 2025
Context: In oncology clinical trials, the primary clinical endpoint is often overall survival (OS), which requires long study duration. Tumor size…
Read morePharmacometric modeling to capture the time varying pharmacokinetics of PEG-asparaginase in acute lymphoblastic leukemia: A multi-protocol analysis from Nordic and Baltic countries
Thursday 16 October, 2025
Introduction: Acute lymphoblastic leukemia (ALL) is the most prevalent form of pediatric cancer, accounting for approximately 6540 new cases and over…
Read morePopulation pharmacokinetic model of encorafenib and binimetinb in real life settings
Thursday 16 October, 2025
Objectives: The RAS/RAF/MEK/ERK signaling pathway plays a pivotal role in the pathogenesis of numerous cancers, leading to the development of…
Read morePopulation pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin
Thursday 16 October, 2025
Objectives: Colorectal cancer (CRC) is a prevalent malignancy, accounting for approximately 10% of all cancer diagnoses worldwide [1]. At onset,…
Read moreThe effect of pH on intratumoural docetaxel release from polymeric nanoparticle CPC634
Thursday 16 October, 2025
Objectives: Docetaxel (DTX), a widely used antimitotic agent for diverse solid cancers, demonstrates great variability in clinical responses. This variability…
Read moreOptimizing IMC-001 Dosage Regimens Using Target Mediated Drug Disposition Model: Enhancing Therapeutic Efficacy and Safety in Cancer Treatment
Thursday 16 October, 2025
Objectives: The emergence of anti-programmed cell death ligand 1 (PD-L1) inhibitors marks a sophisticated approach in cancer therapeutics, strategically addressing…
Read moreSupporting the development and optimization of mRNA-encoded therapeutics through a multiscale Physiologically Based Pharmacokinetic (PBPK) platform
Thursday 16 October, 2025
Introduction: In recent years, antibody-based therapeutics have shown promise, particularly in cancer treatment. However, the high cost of laboratory experiments,…
Read moreA QSP model for predicting efficacy assessment of combined treatment of radiotherapy and anti-PD-1 for NSCLC patients through virtual clinical trials.
Thursday 16 October, 2025
Introduction: Immunotherapy approaches represent a promising paradigm for cancer treatment. This led to an explosion in the number of therapeutic…
Read more